Earnings History Data for Sarepta Therapeutics, Inc. (SRPT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-11-2024	AH		SRPT	Sarepta Therapeutics, Inc.	11,740	0.24	-0.15	-0.46	Sarepta Therapeutics Non-GAAP EPS of $0.62 beats by $0.25, revenue of $467.2M beats by $62.14M [11/6/2024 4:11 PM]	120.58	-7.39 (-5.77%)	132.01	4.04 (3.16%)	75.85 - 173.25	2,066,783	820,000	45,612
Sarepta Therapeutics Non-GAAP EPS of $0.62 beats by $0.25, revenue of $467.2M beats by $62.14M [11/6/2024 4:11 PM] Sarepta upgraded at Cantor on pipeline, growth potential [11/7/2024 12:25 PM] Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments [2024-11-06 04:05PM] Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript [2024-11-07 04:00AM] Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [2024-11-07 02:20AM] Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates [Nov-06-24 06:30PM] Sarepta Therapeutics: Q3 Earnings Snapshot [Nov-06-24 04:22PM]
07-08-2024	AH		SRPT	Sarepta Therapeutics, Inc.	13,610	0.07	0.00	-0.27	Sarepta Therapeutics Non-GAAP EPS of $0.44 misses by $0.03, revenue of $362.9M misses by $24.91M [8/7/2024 4:15 PM]	136.53	-3.53 (-2.52%)	133.50	-6.56 (-4.68%)	55.25 - 173.25	3,072,025	1,140,000	54,865
Sarepta Therapeutics Non-GAAP EPS of $0.44 misses by $0.03, revenue of $362.9M misses by $24.91M [8/7/2024 4:15 PM] Evercore upgrades Sarepta to outperform, but lowers price target [8/8/2024 10:45 AM]
01-05-2024	AH		SRPT	Sarepta Therapeutics, Inc.	12,090	0.38	-0.11	-1.44	Sarepta Therapeutics Non-GAAP EPS of $0.73 beats by $0.43, revenue of $413.5M beats by $43.02M [5/1/2024 4:10 PM]	130.61	-0.29 (-0.22%)	140.00	9.10 (6.95%)	55.25 - 159.89	1,962,546	1,030,000	10,247
Sarepta Therapeutics jumps 5% on Q1 beats [5/1/2024 4:56 PM] Sarepta Therapeutics Non-GAAP EPS of $0.73 beats by $0.43, revenue of $413.5M beats by $43.02M [5/1/2024 4:10 PM] Sarepta Elevidys accelerated approval criticized by ICER exec [5/2/2024 3:36 PM]
28-02-2024	AH		SRPT	Sarepta Therapeutics	12,772	0.47	-0.03	0.00	Sarepta Therapeutics Non-GAAP EPS of $0.82 beats by $0.45, revenue of $396.78M beats by $10.62M [2/28/2024 4:10 PM]	127.92	-9.58 (-6.96%)	138.00	0.50 (0.36%)	55.25 - 159.89	1,624,472	1,020,000	3,225
Sarepta Therapeutics Non-GAAP EPS of $0.82 beats by $0.45, revenue of $396.78M beats by $10.62M [2/28/2024 4:10 PM]
01-11-2023	AH		SRPT	Sarepta Therapeutics, Inc.	10,040	-0.46	-1.63	-2.94	Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M [11/1/2023 4:13 PM]	77.76	1.24 (1.62%)	77.76	0.0 (0.00%)	55.25 - 159.89	3,638,270	3,770,000	12,899
Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M [11/1/2023 4:13 PM]
02-08-2023	AH		SRPT	Sarepta Therapeutics, Inc.	10,100	-0.27	-1.89	-2.65	Sarepta Therapeutics Non-GAAP EPS of -$0.85 beats by $0.15, revenue of $261.2M beats by $5.36M [8/2/2023 4:09 PM]	107.30	2.11 (2.00%)	105.19	0.0 (0.00%)	92.54 - 159.89	1,272,247	980,000	8,410
Sarepta Therapeutics Non-GAAP EPS of -$0.85 beats by $0.15, revenue of $261.2M beats by $5.36M [8/2/2023 4:09 PM]
02-05-2023	AH	4:05 PM ET (May 2)	SRPT	Sarepta Therapeutics, Inc.	11,380	-1.44	-1.46	-1.20	Sarepta Therapeutics GAAP EPS of -$5.86 misses by $4.57, revenue of $253.5M beats by $12.03M [5/2/2023 4:10 PM]	125.55	1.86 (1.50%)	121.00	-2.69 (-2.17%)	61.28 - 159.84	1,153,323	970,000	1,947
Sarepta Therapeutics GAAP EPS of -$5.86 misses by $4.57, revenue of $253.5M beats by $12.03M [5/2/2023 4:10 PM] Sarepta misses badly on bottom line due to $387M loss on debt extinguishment [5/2/2023 5:52 PM]
28-02-2023	AH	4:05 PM ET (Feb 28)	SRPT	Sarepta Therapeutics, Inc.	11,100	-1.24	-1.28	-1.42	Sarepta Therapeutics Q4 results mixed [2/28/2023 4:10 PM]	145.24	23.11 (18.92%)	143.03	20.90 (17.11%)	61.28 - 152.30	6,289,018	1,050,000	179,452
Sarepta Therapeutics Q4 results mixed [2/28/2023 4:10 PM] Sarepta up 16% after no FDA advisory meeting for Duchenne therapy [2/28/2023 5:28 PM] Sarepta gains 18% as Morgan Stanley upgrades citing FDA approval for gene therapy [3/1/2023 8:00 AM]
02-11-2022	AH	4:05 PM ET (Nov 2)	SRPT	Sarepta Therapeutics, Inc.	9,980	-2.94	-1.21	-0.60	Sarepta Therapeutics Non-GAAP EPS of -$0.80 misses by $0.06, revenue of $230.27M misses by $4.28M [11/2/2022 4:18 PM]	105.00	-8.43 (-7.43%)	113.42	0.0 (0.00%)	61.28 - 120.23	2,114,238	940,000	18,027
Sarepta Therapeutics Non-GAAP EPS of -$0.80 misses by $0.06, revenue of $230.27M misses by $4.28M [11/2/2022 4:18 PM] Sarepta misses on top and bottom line in Q3 as net loss more than quadruples [11/2/2022 4:43 PM] Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments [Nov-02-22 04:05PM]
02-08-2022	AH	4:05 PM ET (Aug 2)	SRPT	Sarepta Therapeutics, Inc.	7,350	-2.65	-1.07	-1.02	Sarepta Therapeutics Non-GAAP EPS of -$1.18 misses by $0.58, revenue of $233.49M beats by $12.68M [8/2/2022 4:23 PM]	96.13	2.12 (2.26%)	94.35	0.34 (0.36%)	61.28 - 101.24	2,227,964	910,000	969
Sarepta Therapeutics Non-GAAP EPS of -$1.18 misses by $0.58, revenue of $233.49M beats by $12.68M [8/2/2022 4:23 PM] Sarepta down after-hours following Q2 bottom line miss, but boosts 2022 revenue guidance [8/2/2022 6:09 PM] Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More [Aug-01-22 01:59PM] Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength? [Aug-01-22 08:41AM] When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Breakeven? [Aug-01-22 07:44AM] Top 10 Stock Picks of Eli Casdins Casdin Capital [Aug-02-22 09:11AM] Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments [Aug-02-22 04:05PM]
04-05-2022	AH	4:05 PM ET (May 4)	SRPT	Sarepta Therapeutics	6,328	-1.20	-1.35	0.00	Sarepta Therapeutics Non-GAAP EPS of -$0.56 beats by $0.47, revenue of $210.8M beats by $2.55M [5/4/2022 4:08 PM]	71.18	-1.57 (-2.16%)	75.00	2.25 (3.09%)	61.31 - 101.24	623,074	720,000	1,095
Sarepta Therapeutics Non-GAAP EPS of -$0.56 beats by $0.47, revenue of $210.8M beats by $2.55M [5/4/2022 4:08 PM] Sarepta net loss narrows 37% buoyed by muscular dystrophy therapies revenue increase [5/4/2022 5:10 PM] Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference [May-04-22 08:30AM] Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments [May-04-22 04:05PM] Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates [May-04-22 05:25PM] Sarepta Therapeutics (SRPT) Q1 2022 Earnings Call Transcript [May-05-22 05:30AM] Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust [May-05-22 09:31AM]
01-03-2022	AH	4:00 PM ET (Mar 1)	SRPT	Sarepta Therapeutics, Inc.	6,620	-1.42	-1.21	-2.40	Sarepta Therapeutics Non-GAAP EPS of -$0.77 beats by $0.37, revenue of $201.46M beats by $2.98M [3/1/2022 4:09 PM]	79.63	3.61 (4.75%)	75.00	-1.02 (-1.34%)	61.31 - 101.24	1,085,450	640,000	428
Sarepta Therapeutics Non-GAAP EPS of -$0.77 beats by $0.37, revenue of $201.46M beats by $2.98M [3/1/2022 4:09 PM] Sarepta down 4% after hours despite top and bottom line earnings beats [3/1/2022 4:59 PM] Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Feb-28-22 06:17PM] Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass Estimates [Feb-28-22 08:55AM] Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments [Mar-01-22 04:05PM] Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates [Mar-01-22 05:55PM] Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust [Mar-02-22 10:16AM] Sarepta Therapeutics to Present at Upcoming Investor Conferences [Mar-02-22 04:30PM]
03-11-2021	AH	4:05 PM ET (Nov 3)	SRPT	Sarepta Therapeutics, Inc.	6,890	-0.60	-1.86	-2.50	Sarepta Therapeutics EPS beats by $1.37, beats on revenue, raises product guidance [11/3/2021 4:09 PM]	87.07	0.54 (0.62%)	86.97	-0.10 (-0.11%)	65.30 - 181.83	1,445,797	930,000	24,232
Sarepta Therapeutics EPS beats by $1.37, beats on revenue, raises product guidance [11/3/2021 4:09 PM] Sarepta boosts 2021 revenue guidance by $40M on strong muscular dystrophy meds sales [11/3/2021 4:36 PM] Sarepta Therapeutics to Present at Upcoming Investor Conferences [Nov-02-21 04:30PM] Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments [Nov-03-21 04:01PM] Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates [Nov-03-21 05:25PM] Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript [Nov-04-21 04:31AM] Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised [Nov-04-21 10:08AM] Why Sarepta Therapeutics Shares Dropped More Than 16% This Week [Nov-04-21 06:23PM]
04-08-2021	AH	4:05 PM ET (Aug 4)	SRPT	Sarepta Therapeutics, Inc.	5,470	-1.02	-1.03	-1.93	Sarepta Therapeutics EPS misses by $0.23, beats on revenue [8/4/2021 4:16 PM]	78.53	11.03 (16.34%)	71.77	4.27 (6.33%)	65.30 - 181.83	2,297,537	640,000	39,045
Sarepta executes licensing agreement for gene therapy program in muscular dystrophy [8/4/2021 8:40 AM] Sarepta Therapeutics EPS misses by $0.23, beats on revenue [8/4/2021 4:16 PM] Sarepta Therapeutics narrows Q2 net loss thanks to one-off gain [8/4/2021 4:35 PM] Sarepta upgraded to neutral at J.P. Morgan on regulatory and pipeline progress [8/5/2021 9:00 AM] Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Childrens Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A [Aug-04-21 08:30AM] Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments [Aug-04-21 04:05PM] Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates [Aug-04-21 05:55PM] Sarepta Therapeutics (SRPT) Q2 2021 Earnings Call Transcript [Aug-05-21 04:01AM] Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised [Aug-05-21 09:23AM]
05-05-2021	AH	4:05 PM ET (May 5)	SRPT	Sarepta Therapeutics, Inc.	5,650	-2.10	-2.01	-0.23	Sarepta Therapeutics EPS beats by $0.03, beats on revenue [5/5/2021 4:13 PM]	74.61	1.84 (2.53%)	74.61	0.0 (0.00%)	68.04 - 181.83	2,082,817	1,070,000	12,769
Sarepta Therapeutics to Present at Upcoming Investor Conferences [May-04-21 04:30PM] Sarepta Therapeutics, Inc. to Host Earnings Call [May-05-21 02:45PM] Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments [May-05-21 04:05PM] Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates [May-05-21 07:15PM] Sarepta Therapeutics (SRPT) Q1 2021 Earnings Call Transcript [May-06-21 03:01AM]
01-03-2021	AH	4:05 PM ET (Mar 1)	SRPT	Sarepta Therapeutics, Inc.	6,730	-2.40	-1.99	-3.16	Sarepta Therapeutics EPS misses by $0.38, misses on revenue [3/1/2021 4:09 PM]	88.83	1.80 (2.07%)	85.00	-2.03 (-2.33%)	77.01 - 181.83	1,566,140	1,488,746	13,431
Sarepta Therapeutics EPS misses by $0.38, misses on revenue [3/1/2021 4:09 PM] Sarepta slides on revenue miss [3/1/2021 4:47 PM] Sarepta Therapeutics Stock Drops on Earnings. Why Analysts Remain Hopeful. [Mar-02-21 08:57AM] Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments [Mar-01-21 04:05PM] Sarepta Therapeutics, Inc. to Host Earnings Call [Mar-01-21 02:30PM]
05-11-2020	AH	4:05 PM ET (Nov 5)	SRPT	Sarepta Therapeutics, Inc.	11,100	-2.50	-1.89	-1.70	Sarepta Therapeutics EPS misses by $0.02, beats on revenue [11/5/2020 4:26 PM]	125.66	-19.49 (-13.43%)	141.00	-4.15 (-2.86%)	78.06 - 175.00	4,365,515	585,144	72,417

05-08-2020	AH	4:05 PM ET (Aug 5)	SRPT	Sarepta Therapeutics, Inc.	11,970	-1.93	-1.73	-3.74	Sarepta Therapeutics EPS misses by $0.20, beats on revenue [8/5/2020 4:10 PM]	154.52	-4.36 (-2.75%)	157.00	-1.89 (-1.19%)	72.05 - 175.00	377,442	602,323	341

06-05-2020	AH		SRPT	Sarepta Therapeutics, Inc.	9,230	-0.23	-2.17	-1.07		0.0	0.0 (0.00%)	0.0	0.0 (0.00%)	0.0 - 0.0	0	0	0